Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	Spectrum Pharmaceuticals	Viking Therapeutics	Forte Biosciences	Molecular Templates	Geron
Symbol	NASDAQ:SPPI	NASDAQ:VKTX	NASDAQ:FBRX	NASDAQ:MTEM	NASDAQ:GERN
Price Information
Current Price	$3.48	$6.17	$31.61	$7.86	$1.43
52 Week Range	Buy	Buy	Buy	Buy	Buy
MarketRank™
Overall Score	1.5	1.6	1.7	2.0	1.4
Analysis Score	3.4	3.6	3.5	3.4	3.5
Community Score	2.8	3.5	3.5	2.6	2.7
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	0.8	0.8	0.8	3.3	0.8
Earnings & Valuation Score	0.6	0.0	0.6	0.6	0.0
Analyst Ratings
Consensus Recommendation	Buy	Buy	Buy	Buy	Buy
Consensus Price Target	$9.75	$16.89	$80.50	$14.50	$4.20
% Upside from Price Target	180.17% upside	173.73% upside	154.67% upside	84.48% upside	193.71% upside
Trade Information
Market Cap	$541.88 million	$481.88 million	$427.11 million	$440.85 million	$455.55 million
Beta	2.51	2.02	0.23	2.08	1.5
Average Volume	2,604,234	1,259,706	173,876	433,353	3,279,361
Sales & Book Value
Annual Revenue	$109.33 million	N/A	$40,000.00	$22.27 million	$460,000.00
Price / Sales	4.96	N/A	10,677.86	19.80	990.33
Cashflow	N/A	N/A	N/A	N/A	N/A
Price / Cash	N/A	N/A	N/A	N/A	N/A
Book Value	$1.69 per share	$3.83 per share	$6.81 per share	$2.79 per share	$0.68 per share
Price / Book	2.06	N/A	4.64	2.82	2.10
Profitability
Net Income	$-112,690,000.00	$-25,780,000.00	$-63,520,000.00	$-69,420,000.00	$-68,550,000.00
EPS	($1.14)	($0.36)	($40.33)	($1.26)	($0.36)
Trailing P/E Ratio	N/A	N/A	N/A	N/A	N/A
Forward P/E Ratio	N/A	N/A	N/A	N/A	N/A
P/E Growth	N/A	N/A	N/A	N/A	N/A
Net Margins	N/A	N/A	N/A	-428.65%	-21,631.02%
Return on Equity (ROE)	-98.90%	-13.57%	-417.87%	-111.43%	-43.76%
Return on Assets (ROA)	-69.77%	-13.14%	-248.28%	-56.35%	-37.24%
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	0.05%	N/A	N/A	0.18%	0.10%
Current Ratio	3.48%	27.08%	8.97%	3.21%	9.60%
Quick Ratio	3.48%	27.09%	8.97%	3.21%	9.60%
Ownership Information
Institutional Ownership Percentage	63.56%	54.13%	53.03%	60.73%	55.51%
Insider Ownership Percentage	5.04%	3.70%	10.90%	38.20%	7.70%
Miscellaneous
Employees	175	18	9	236	53
Shares Outstanding	155.71 million	78.10 million	13.51 million	56.09 million	318.57 million
Next Earnings Date	8/9/2021 (Estimated)	8/4/2021 (Estimated)	8/9/2021 (Estimated)	8/5/2021 (Estimated)	8/5/2021 (Estimated)
Optionable	Optionable	Optionable	Not Optionable	Not Optionable	Optionable

Source	Headline
	Geron Co. Expected to Earn Q2 2021 Earnings of ($0.09) Per Share (NASDAQ:GERN) americanbankingnews.com - May 14 at 8:56 AM
	Geron Co. (NASDAQ:GERN) Expected to Announce Quarterly Sales of $80,000.00 americanbankingnews.com - May 14 at 1:22 AM
	Geron Announces Two Presentations at Upcoming European Hematology Association Annual Congress - Business Wire businesswire.com - May 13 at 3:33 AM
	Geron Co. (NASDAQ:GERN) Expected to Post Earnings of -$0.08 Per Share americanbankingnews.com - May 12 at 7:18 PM
	Geron Announces Two Presentations at Upcoming European Hematology Association Annual Congress - Yahoo Finance finance.yahoo.com - May 12 at 5:17 PM
	Geron Announces Two Presentations at Upcoming European Hematology Association Annual Congress - Galveston County Daily News galvnews.com - May 12 at 12:15 PM
	Geron Announces Two Presentations at Upcoming European Hematology Association Annual Congress finance.yahoo.com - May 12 at 12:15 PM
$Trial to Investigate Experimental Drugs Effect on Improving Survival in Refractory Myelofibrosis - Curetoday.com$	Trial to Investigate Experimental Drug's Effect on Improving Survival in Refractory Myelofibrosis - Curetoday.com curetoday.com - May 11 at 5:55 PM
	Geron: Q1 Earnings Snapshot - Greenwich Time greenwichtime.com - May 11 at 5:55 PM
	Is it Time to Dump Geron Corporation (GERN) Stock After it Has Fallen 2.92% in a Week? - InvestorsObserver investorsobserver.com - May 11 at 5:55 PM
	Analysts’ Top Healthcare Picks: Avadel Pharmaceuticals (AVDL), Geron (GERN) - Smarter Analyst smarteranalyst.com - May 11 at 12:54 PM
	Geron (GERN) Received its Third Buy in a Row - Smarter Analyst smarteranalyst.com - May 11 at 12:54 PM
	Geron: Q1 Earnings Snapshot - Centre Daily Times centredaily.com - May 11 at 12:54 PM
	Geron (GERN) Q1 2021 Earnings Call Transcript - Motley Fool fool.com - May 11 at 12:54 PM
	Geron (NASDAQ:GERN) Announces Earnings Results, Misses Expectations By $0.01 EPS americanbankingnews.com - May 11 at 12:34 PM
	Geron: Q1 Earnings Snapshot - San Francisco Chronicle sfchronicle.com - May 11 at 7:54 AM
	Geron (GERN) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance finance.yahoo.com - May 11 at 7:54 AM
	Geron (GERN) Q1 2021 Earnings Call Transcript finance.yahoo.com - May 11 at 7:54 AM
	Washington Lineman Cornelius Lucas Fires Back At Media 'Clowns' - Sports Illustrated si.com - May 11 at 12:16 AM
	Geron: Q1 Earnings Snapshot - Modesto Bee modbee.com - May 11 at 12:16 AM
	Geron (GERN) Reports Q1 Loss, Tops Revenue Estimates - Nasdaq nasdaq.com - May 10 at 7:15 PM
	Geron: Q1 Earnings Insights - Benzinga benzinga.com - May 10 at 7:15 PM
	Geron: Q1 Earnings Snapshot - Sacramento Bee sacbee.com - May 10 at 7:15 PM
	Geron Corporation Reports First Quarter 2021 Financial Results and Recent Highlights - Business Wire businesswire.com - May 10 at 7:15 PM
	Geron (GERN) Reports Q1 Loss, Tops Revenue Estimates finance.yahoo.com - May 10 at 7:15 PM

Date	Company	Brokerage	Action
4/12/2021	Spectrum Pharmaceuticals	B. Riley	Reiterated Rating
10/26/2020	Spectrum Pharmaceuticals	HC Wainwright	Lower Price Target
9/17/2020	Spectrum Pharmaceuticals	JMP Securities	Initiated Coverage
7/28/2020	Spectrum Pharmaceuticals	Cantor Fitzgerald	Boost Price Target
12/26/2019	Spectrum Pharmaceuticals	Guggenheim	Downgrade
3/15/2019	Spectrum Pharmaceuticals	Jefferies Financial Group	Reiterated Rating
5/3/2021	Viking Therapeutics	SVB Leerink	Reiterated Rating
1/22/2021	Viking Therapeutics	Stifel Nicolaus	Reiterated Rating
10/29/2020	Viking Therapeutics	Raymond James	Boost Price Target
9/11/2020	Viking Therapeutics	William Blair	Reiterated Rating
9/1/2020	Viking Therapeutics	BTIG Research	Boost Price Target
8/31/2020	Viking Therapeutics	Chardan Capital	Boost Price Target
7/29/2020	Viking Therapeutics	Oppenheimer	Reiterated Rating
6/4/2020	Viking Therapeutics	BMO Capital Markets	Initiated Coverage
5/2/2020	Viking Therapeutics	Maxim Group	Initiated Coverage
4/1/2021	Forte Biosciences	Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell	Initiated Coverage
3/26/2021	Forte Biosciences	(FBRC)	Initiated Coverage
8/28/2020	Forte Biosciences	Brookline Capital Management	Initiated Coverage
8/25/2020	Forte Biosciences	Truist Securiti	Initiated Coverage
6/22/2020	Forte Biosciences	LADENBURG THALM/SH SH	Initiated Coverage
4/27/2021	Molecular Templates	Bank of America	Initiated Coverage
2/1/2021	Molecular Templates	UBS Group	Initiated Coverage
2/27/2020	Molecular Templates	Barclays	Initiated Coverage
11/13/2019	Molecular Templates	Cowen	Reiterated Rating
12/11/2018	Molecular Templates	CIBC	Initiated Coverage
11/15/2018	Molecular Templates	Evercore ISI	Initiated Coverage
10/8/2018	Molecular Templates	Laidlaw	Initiated Coverage
6/17/2020	Geron	Needham & Company LLC	Reiterated Rating
9/27/2018	Geron	S&P Equity Research	Lower Price Target

(Data available from 5/16/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources